Mauro Scaravilli

Mauro Scaravilli

Auto-generated profile, based on publicly available information

Mauro Scaravilli

Institute of Biomedicine, University of Eastern Finland, FI-70210 Kuopio, Finland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2016 in Oncotarget
Verified
Journal Article
Open access
MOMichael Olvedy
Michael Olvedy
MSMauro Scaravilli
Mauro Scaravilli
YHYouri Hoogstrate
Youri Hoogstrate
TVTapio Visakorpi
Tapio Visakorpi
GJGuido Jenster
Guido Jenster
EMElena S. Martens-Uzunova
Elena S. Martens-Uzunova
A comprehensive repertoire of tRNA-derived fragments in prostate cancer A comprehensive repertoire of tRNA-derived fragments in prostate cancer

30 September 2015 in Cancer Research
Verified
Journal Article
Open access
PDF file
AYAntti Ylipää
Antti Ylipää
KKKati Kivinummi
Kati Kivinummi
AKAnnika Kohvakka
Annika Kohvakka
MAMatti Annala
Matti Annala
Leena LatonenLeena Latonen
Leena Latonen
MNMatti Nykter
Matti Nykter
Castration-resistant prostate cancers (CRPC) that arise after the failure of androgen-blocking therapies cause most of the deaths from prostate cancer, intensifying the need to fully understand CRPC pathophysiology. In this study, we characterized the transcriptomic differences between untreated prostate cancer and locally recurrent CRPC. Here, we report the identification of 145 previously unannotated intergenic long noncoding RNA transcripts (lncRNA) or isoforms that are associated with prostate cancer or CRPC. Of the one third of these transcripts that were specific for CRPC, we defined a novel lncRNA termed PCAT5 as a regulatory target for the transcription factor ERG, which is activated in approximately 50% of human prostate cancer. Genome-wide expression analysis of a PCAT5-positive prostate cancer after PCAT5 silencing highlighted alterations in cell proliferation pathways. Strikingly, an in vitro validation of these alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, colony-forming potential, and apoptosis. Our findings reveal a key molecular determinant of differences between prostate cancer and CRPC at the level of the transcriptome. Furthermore, they establish PCAT5 as a novel oncogenic lncRNA in ERG-positive prostate cancers, with implications for defining CRPC biomarkers and new therapeutic interventions. Cancer Res; 75(19); 4026–31. ©2015 AACR.

1 January 2015 in European Urology
Verified
Journal Article
Closed access
JRJayant K. Rane
Jayant K. Rane
MSMauro Scaravilli
Mauro Scaravilli
AYAntti Ylipää
Antti Ylipää
DPDavide Pellacani
Davide Pellacani
VMVincent M. Mann
Vincent M. Mann
NMNorman Maitland
Norman Maitland

1 March 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
MSMauro Scaravilli
Mauro Scaravilli
KPKati P. Porkka
Kati P. Porkka
ABAnniina Brofeldt
Anniina Brofeldt
MAMatti Annala
Matti Annala
TTTeuvo Lj. Tammela
Teuvo Lj. Tammela
TVTapio Visakorpi
Tapio Visakorpi

1 July 2015 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KKKirsi M. Kaukoniemi
Kirsi M. Kaukoniemi
HRHanna E. Rauhala
Hanna E. Rauhala
MSMauro Scaravilli
Mauro Scaravilli
Leena LatonenLeena Latonen
Leena Latonen
MAMatti Annala
Matti Annala
TVTapio Visakorpi
Tapio Visakorpi
Micro‐RNAs (miRNA) are important regulators of gene expression and often differentially expressed in cancer and other diseases. We have previously shown that miR‐193b is hypermethylated in prostate cancer (PC) and suppresses cell growth. It has been suggested that miR‐193b targets cyclin D1 in several malignancies. Here, our aim was to determine if miR‐193b targets cyclin D1 in prostate cancer. Our data show that miR‐193b is commonly methylated in PC samples compared to benign prostate hyperplasia. We found reduced miR‐193b expression (P < 0.05) in stage pT3 tumors compared to pT2 tumors in a cohort of prostatectomy specimens. In 22Rv1 PC cells with low endogenous miR‐193b expression, the overexpression of miR‐193b reduced CCND1 mRNA levels and cyclin D1 protein levels. In addition, the exogenous expression of miR‐193b decreased the phosphorylation level of RB, a target of the cyclin D1‐CDK4/6 pathway. Moreover, according to a reporter assay, miR‐193b targeted the 3’UTR of CCND1 in PC cells and the CCND1 activity was rescued by expressing CCND1 lacking its 3’UTR. Immunohistochemical analysis of cyclin D1 showed that castration‐resistant prostate cancers have significantly (P = 0.0237) higher expression of cyclin D1 compared to hormone‐naïve cases. Furthermore, the PC cell lines 22Rv1 and VCaP, which express low levels of miR‐193b and high levels of CCND1, showed significant growth retardation when treated with a CDK4/6 inhibitor. In contrast, the inhibitor had no effect on the growth of PC‐3 and DU145 cells with high miR‐193b and low CCND1 expression. Taken together, our data demonstrate that miR‐193b targets cyclin D1 in prostate cancer.

1 July 2020 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
KSKalle Savolainen
Kalle Savolainen
MSMauro Scaravilli
Mauro Scaravilli
AIAntti Ilvesmäki
Antti Ilvesmäki
SSSynnöve Staff
Synnöve Staff
TTTeemu Tolonen
Teemu Tolonen
AAAnnika Auranen
Annika Auranen
Objective: Plasma, but also urine sample could represent a simple liquid biopsy for ovarian cancer biomarker detection. The miRNA-200 family has been shown to be dysregulated in ovarian cancer. The aim of this study was to isolate three members of miR-200 family from tumor tissue, plasma and urine of high-grade serous ovarian cancer patients in comparison with samples from patients with benign ovarian tumors. This is a methodological pilot study of a prospective ovarian cancer patient cohort investigating the potential of liquid biopsies and the role of miRNAs in ovarian cancer treatment. Results: MiR-200a, miR-200b and miR-200c were isolated from samples of nine ovarian cancer patients and seven patients with benign ovarian tumor. The most significant finding is that all three miRNAs were detectable in all sample types. Tumor tissue and plasma, but not urine analysis was able to discriminate malignant and benign samples. A correlation between the miRNA-200 expression in urine and plasma was observed in malignant samples only. Plasma and urine with respect to miRNA detection show potential according to this study, but larger studies are needed to clarify the usefulness of these liquid biopsies in ovarian cancer. Trial registration: ClinicalTrials.gov NCT02758652, May 2, 2016.